Comparing the Gonadotoxicity of Multiple Breast Cancer Regimens: Important Understanding for Managing Breast Cancer in Pre-Menopausal Women

References

• SungH, FerlayJ, SiegelRL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021:41.
   Web of Science ®Google Scholar
• Paluch-ShimonS, CardosoF, PartridgeAH, et al. ESO–ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4). Ann Oncol. 2020;31(6):674–696. doi:10.1016/j.annonc.2020.03.28432199930
   PubMed Web of Science ®Google Scholar
• FidlerMM, GuptaS, SoerjomataramI, FerlayJ, Steliarova-FoucherE, BrayF. Cancer incidence and mortality among young adults aged 20–39 years worldwide in 2012: a population-based study. Lancet Oncol. 2017;18(12):1579–1589. doi:10.1016/S1470-2045(17)30677-029111259
   PubMed Web of Science ®Google Scholar
• SiegelRL, MillerKD, JemalA. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.2159031912902
   PubMed Web of Science ®Google Scholar
• GhiasvandR, AdamiH-O, HarirchiI, AkramiR, ZendehdelK. Higher incidence of premenopausal breast cancer in less developed countries; myth or truth?BMC Cancer. 2014;14(1):343. doi:10.1186/1471-2407-14-34324884841
   PubMed Web of Science ®Google Scholar
• HarbeckN, GnantM. Breast cancer. The Lancet. 2017;389(10074):1134–1150. doi:10.1016/S0140-6736(16)31891-8
   PubMed Web of Science ®Google Scholar
• Caparica R, BruzzoneM, Poggio F, et al. Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials. Breast Cancer Res Treat. 2019;174(1):27-37.
   Google Scholar
• Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020;382(9):810–821. doi:10.1056/NEJMoa1910549
   Google Scholar
• MittendorfEA, ZhangH, BarriosCH, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. The Lancet. 2020;396(10257):1090–1100. doi:10.1016/S0140-6736(20)31953-X
   PubMed Web of Science ®Google Scholar
• CardosoF, KyriakidesS, OhnoS, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(8):1194–1220. doi:10.1093/annonc/mdz17331161190
   PubMed Web of Science ®Google Scholar
• KordeLA, SomerfieldMR, CareyLA, et al. Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. J Clin Oncol. 2021:JCO.20.03399. doi:10.1200/JCO.20.03399
   Web of Science ®Google Scholar
• BursteinHJ, LacchettiC, AndersonH, et al. Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. J Clin Oncol. 2019;37(5):423–438. doi:10.1200/JCO.18.0116030452337
   PubMed Web of Science ®Google Scholar
• LambertiniM, BlondeauxE, PerroneF, Del MastroL. Improving adjuvant endocrine treatment tailoring in premenopausal women with hormone receptor–positive breast cancer. J Clin Oncol. 2020;38(12):1258–1267. doi:10.1200/JCO.19.0224231618128
   PubMed Web of Science ®Google Scholar
• LambertiniM, PeccatoriFA, DemeestereI, et al. Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines†. Ann Oncol. 2020;31(12):1664–1678. doi:10.1016/j.annonc.2020.09.00632976936
   PubMed Web of Science ®Google Scholar
• AndersonRA, AmantF, BraatD; The ESHRE Guideline Group on Female Fertility Preservation. ESHRE guideline: female fertility preservation†. Hum Reprod Open. 2020;2020(4):hoaa052. doi:10.1093/hropen/hoaa05233225079
   PubMedGoogle Scholar
• LetourneauJM, EbbelEE, KatzPP, et al. Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer. Cancer. 2012;118(6):1710–1717. doi:10.1002/cncr.2645921887678
   PubMed Web of Science ®Google Scholar
• Franzoi MA, Agostinetto E, Perachino M, et al.Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer. Lancet Oncol.2021. doi:10.1016/S1470-2045(20)30666-5.
   Google Scholar
• OktayK, HarveyBE, PartridgeAH, et al. Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2018;36(19):1994–2001. doi:10.1200/JCO.2018.78.191429620997
   PubMed Web of Science ®Google Scholar
• CardosoF, Paluch-ShimonS, SenkusE, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31(12):1623–1649. doi:10.1016/j.annonc.2020.09.01032979513
   PubMed Web of Science ®Google Scholar
• LambertiniM, AnseriniP, LevaggiA, PoggioF, MastroLD. Fertility counseling of young breast cancer patients. J Thorac Dis. 2013;5(1):S68–80. doi:10.3978/j.issn.2072-1439.2013.05.2223819030
   PubMed Web of Science ®Google Scholar
• von WolffM, CappE, JauckusJ, StrowitzkiT, GermeyerA. Timing of ovarian stimulation in patients prior to gonadotoxic therapy: an analysis of 684 stimulations. Eur J Obstet Gynecol Reprod Biol. 2016;199:146–149. doi:10.1016/j.ejogrb.2016.02.00626927896
   PubMed Web of Science ®Google Scholar
• RienziL, GraciaC, MaggiulliR, et al. Oocyte, embryo and blastocyst cryopreservation in ART: systematic review and meta-analysis comparing slow-freezing versus vitrification to produce evidence for the development of global guidance. Hum Reprod Update. 2016. doi:10.1093/humupd/dmw038
   Web of Science ®Google Scholar
• LambertiniM, HoricksF, Del mastroL, PartridgeAH, DemeestereI. Ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy in cancer patients: from biological evidence to clinical application. Cancer Treat Rev. 2019;72:65–77. doi:10.1016/j.ctrv.2018.11.00630530271
   PubMed Web of Science ®Google Scholar
• RuddyKJ, GelberSI, TamimiRM, et al. Prospective Study of Fertility Concerns and Preservation Strategies in Young Women With Breast Cancer. J Clin Oncol. 2014;32(11):1151–1156. doi:10.1200/JCO.2013.52.887724567428
   PubMed Web of Science ®Google Scholar
• LambertiniM, Di MaioM, PaganiO, et al. The BCY3/BCC 2017 survey on physicians’ knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients. The Breast. 2018;42:41–49. doi:10.1016/j.breast.2018.08.09930170202
   PubMed Web of Science ®Google Scholar
• RuggeriM, PaganE, BagnardiV, et al. Fertility concerns, preservation strategies and quality of life in young women with breast cancer: baseline results from an ongoing prospective cohort study in selected European Centers. The Breast. 2019;47:85–92. doi:10.1016/j.breast.2019.07.00131362134
   PubMed Web of Science ®Google Scholar
• LeeRJ, WakefieldA, FoyS, HowellSJ, WardleyAM, ArmstrongAC. Facilitating reproductive choices: the impact of health services on the experiences of young women with breast cancer. Psychooncology. 2011;20(10):1044–1052. doi:10.1002/pon.182620818600
   PubMed Web of Science ®Google Scholar
• GoossensJ, DelbaereI, Van LanckerA, BeeckmanD, VerhaegheS, Van HeckeA. Cancer patients’ and professional caregivers’ needs, preferences and factors associated with receiving and providing fertility-related information: a mixed-methods systematic review. Int J Nurs Stud. 2014;51(2):300–319. doi:10.1016/j.ijnurstu.2013.06.01523870448
   PubMed Web of Science ®Google Scholar
• CovelliA, FaceyM, KennedyE, et al. Clinicians’ Perspectives on Barriers to Discussing Infertility and Fertility Preservation With Young Women With Cancer. JAMA Netw Open. 2019;2(11):e1914511. doi:10.1001/jamanetworkopen.2019.1451131693121
   PubMed Web of Science ®Google Scholar
• OktayK, TuranV, BedoschiG, PachecoFS, MoyF. Fertility Preservation Success Subsequent to Concurrent Aromatase Inhibitor Treatment and Ovarian Stimulation in Women With Breast Cancer. J Clin Oncol off J Am Soc Clin Oncol. 2015;33(22):2424–2429. doi:10.1200/JCO.2014.59.3723
   PubMed Web of Science ®Google Scholar
• Diaz-GarciaC, DomingoJ, Garcia-VelascoJA, et al. Oocyte vitrification versus ovarian cortex transplantation in fertility preservation for adult women undergoing gonadotoxic treatments: a prospective cohort study. Fertil Steril. 2018;109(3):478–485.e2. doi:10.1016/j.fertnstert.2017.11.01829428307
   PubMed Web of Science ®Google Scholar
• CoboA, García-VelascoJ, DomingoJ, PellicerA, RemohíJ. Elective and Onco-fertility preservation: factors related to IVF outcomes. Hum Reprod. 2018;33(12):2222–2231. doi:10.1093/humrep/dey32130383235
   PubMed Web of Science ®Google Scholar
• GellertSE, PorsSE, KristensenSG, Bay-BjørnAM, ErnstE, Yding AndersenC. Transplantation of frozen-thawed ovarian tissue: an update on worldwide activity published in peer-reviewed papers and on the Danish cohort. J Assist Reprod Genet. 2018;35(4):561–570. doi:10.1007/s10815-018-1144-229497953
   PubMed Web of Science ®Google Scholar
• MeirowD, Ra’ananiH, ShapiraM, et al. Transplantations of frozen-thawed ovarian tissue demonstrate high reproductive performance and the need to revise restrictive criteria. Fertil Steril. 2016;106(2):467–474. doi:10.1016/j.fertnstert.2016.04.03127181924
   PubMed Web of Science ®Google Scholar
• PachecoF, OktayK. Current Success and Efficiency of Autologous Ovarian Transplantation: a Meta-Analysis. Reprod Sci Thousand Oaks Calif. 2017;24(8):1111–1120. doi:10.1177/1933719117702251
   PubMed Web of Science ®Google Scholar
• LambertiniM, MooreHCF, LeonardRCF, et al. Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: a Systematic Review and Meta-Analysis of Individual Patient–Level Data. J Clin Oncol. 2018;36(19):1981–1990. doi:10.1200/JCO.2018.78.085829718793
   PubMed Web of Science ®Google Scholar
• SuHI, HaunschildC, ChungK, et al. Pre-chemotherapy anti-mullerian hormone, age and body size predict timing of return of ovarian function in young breast cancer patients. Cancer. 2014;120(23):3691–3698. doi:10.1002/cncr.2894225081546
   PubMed Web of Science ®Google Scholar
• SilvaC, CarameloO, Almeida-SantosT, Ribeiro RamaAC. Factors associated with ovarian function recovery after chemotherapy for breast cancer: a systematic review and meta-analysis. Hum Reprod. 2016;31(12):2737–2749. doi:10.1093/humrep/dew22427664208
   PubMed Web of Science ®Google Scholar
• LeeS, KilWJ, ChunM, et al. Chemotherapy-related amenorrhea in premenopausal women with breast cancer: menopause. Menopause (New York, N.Y.). 2009;16(1):98–103. doi:10.1097/gme.0b013e3181844877
   PubMed Web of Science ®Google Scholar
• Practice Committee of the American Society for Reproductive Medicine. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril. 2015;103(3):e9–e17. doi:10.1016/j.fertnstert.2014.12.09325585505
   PubMed Web of Science ®Google Scholar
• TalR, SeiferDB. Ovarian reserve testing: a user’s guide. Am J Obstet Gynecol. 2017;217(2):129–140. doi:10.1016/j.ajog.2017.02.02728235465
   PubMed Web of Science ®Google Scholar
• AndersonRA, CameronDA. Pretreatment Serum Anti-Müllerian Hormone Predicts Long-Term Ovarian Function and Bone Mass after Chemotherapy for Early Breast Cancer. J Clin Endocrinol Metab. 2011;96(5):1336–1343. doi:10.1210/jc.2010-258221325458
   PubMed Web of Science ®Google Scholar
• AndersonRA, MansiJ, ColemanRE, AdamsonDJA, LeonardRCF. The utility of anti-Müllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer. Eur J Cancer. 2017;87:58–64. doi:10.1016/j.ejca.2017.10.00129117576
   PubMed Web of Science ®Google Scholar
• FréourT, BarrièreP, MassonD. Anti-müllerian hormone levels and evolution in women of reproductive age with breast cancer treated with chemotherapy. Eur J Cancer. 2017;74:1–8. doi:10.1016/j.ejca.2016.12.00828135602
   PubMed Web of Science ®Google Scholar
• LoubersacS, DezellusA, LefebvreT, et al. Evolution of serum Anti-Müllerian Hormone (AMH) level in young women treated with chemotherapy for breast cancer according to basal AMH level. Eur J Obstet Gynecol Reprod Biol. 2020;254:132–137. doi:10.1016/j.ejogrb.2020.09.01632971432
   PubMed Web of Science ®Google Scholar
• DillonKE, SammelMD, PrewittM, et al. Pre-treatment amh determines rate of post-therapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy. Fertil Steril. 2013;99(2):477–483. doi:10.1016/j.fertnstert.2012.09.03923084267
   PubMed Web of Science ®Google Scholar
• LambertiniM, GoldratO, TossA, et al. Fertility and pregnancy issues in BRCA-mutated breast cancer patients. Cancer Treat Rev. 2017;59:61–70. doi:10.1016/j.ctrv.2017.07.00128750297
   PubMed Web of Science ®Google Scholar
• VukovićP, PeccatoriFA, MassarottiC, MirallesMS, Beketić-OreškovićL, LambertiniM. Preimplantation genetic testing for carriers of BRCA1/2 pathogenic variants. Crit Rev Oncol Hematol. 2021;157:103201. doi:10.1016/j.critrevonc.2020.10320133333149
   PubMed Web of Science ®Google Scholar
• TuranV, OktayK. BRCA-related ATM-mediated DNA double-strand break repair and ovarian aging. Hum Reprod Update. 2020;26(1):43–57. doi:10.1093/humupd/dmz04331822904
   PubMed Web of Science ®Google Scholar
• TuranV, Lambertini M, Lee DY, et al. Association of Germline BRCA Pathogenic Variants With Diminished Ovarian Reserve: A Meta-Analysis of Individual Patient-Level Data. J Clin Oncol. 2021. doi:10.1200/JCO.20.02880
   Web of Science ®Google Scholar
• LambertiniM, GoldratO, FerreiraAR, et al. Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients. Ann Oncol. 2018;29(1):237–243. doi:10.1093/annonc/mdx63929045555
   PubMed Web of Science ®Google Scholar
• ValentiniA, FinchA, LubińskiJ, et al. Chemotherapy-Induced Amenorrhea in Patients With Breast Cancer With a BRCA1 or BRCA2 Mutation. J Clin Oncol. 2013;31(31):3914–3919. doi:10.1200/JCO.2012.47.789323980083
   PubMed Web of Science ®Google Scholar
• LambertiniM, OlympiosN, LequesneJ, et al. Impact of Taxanes, Endocrine Therapy, and Deleterious Germline BRCA Mutations on Anti-müllerian Hormone Levels in Early Breast Cancer Patients Treated With Anthracycline- and Cyclophosphamide-Based Chemotherapy. Front Oncol. 2019;9:575. doi:10.3389/fonc.2019.0057531355134
   PubMed Web of Science ®Google Scholar
• OktayKH, BedoschiG, GoldfarbSB, et al. Increased chemotherapy-induced ovarian reserve loss in women with germline BRCA mutations due to oocyte deoxyribonucleic acid double strand break repair deficiency. Fertil Steril. 2020;113(6):1251–1260.e1. doi:10.1016/j.fertnstert.2020.01.03332331767
   PubMed Web of Science ®Google Scholar
• AbusiefME, MissmerSA, GinsburgES, WeeksJC, PartridgeAH. Relationship between reproductive history, anthropometrics, lifestyle factors, and the likelihood of persistent chemotherapy-related amenorrhea in women with premenopausal breast cancer. Fertil Steril. 2012;97(1):154–159. doi:10.1016/j.fertnstert.2011.10.00522192139
   PubMed Web of Science ®Google Scholar
• RuddyKJ, SchaidDJ, PartridgeAH, et al. Genetic predictors of chemotherapy-related amenorrhea in women with breast cancer. Fertil Steril. 2019;112(4):731–739.e1. doi:10.1016/j.fertnstert.2019.05.01831371054
   PubMed Web of Science ®Google Scholar
• GoldmanKN, ChenetteD, ArjuR, et al. mTORC1/2 inhibition preserves ovarian function and fertility during genotoxic chemotherapy. PNAS. 2017;114(12):3186–3191. doi:10.1073/pnas.161723311428270607
   PubMed Web of Science ®Google Scholar
• Codacci-PisanelliG, Del PupL, Del GrandeM, PeccatoriFA. Mechanisms of chemotherapy-induced ovarian damage in breast cancer patients. Crit Rev Oncol Hematol. 2017;113:90–96. doi:10.1016/j.critrevonc.2017.03.00928427528
   PubMed Web of Science ®Google Scholar
• ZhaoJ, LiuJ, ChenK, et al. What lies behind chemotherapy-induced amenorrhea for breast cancer patients: a meta-analysis. Breast Cancer Res Treat. 2014;145(1):113–128. doi:10.1007/s10549-014-2914-x24671358
   PubMed Web of Science ®Google Scholar
• LambertiniM, Del MastroL, PescioMC, et al. Cancer and fertility preservation: international recommendations from an expert meeting. BMC Med. 2016;14(1):1. doi:10.1186/s12916-015-0545-726728489
   PubMed Web of Science ®Google Scholar
• LambertiniM, CampbellC, BinesJ, et al. Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients. JNCI J Natl Cancer Inst. 2019;111(1):86–94. doi:10.1093/jnci/djy09429878225
   PubMed Web of Science ®Google Scholar
• EjlertsenB, TuxenMK, JakobsenEH, et al. Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A – Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial. J Clin Oncol. 2017;35(23):2639–2646. doi:10.1200/JCO.2017.72.349428661759
   PubMed Web of Science ®Google Scholar
• LambertiniM, CeppiM, CognettiF, et al. Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: a pooled analysis of the MIG1 and GIM2 Phase III studies. Eur J Cancer. 2017;71:34–42. doi:10.1016/j.ejca.2016.10.03027951450
   PubMed Web of Science ®Google Scholar
• MorarjiK, McArdleO, HuiK, et al. Ovarian function after chemotherapy in young breast cancer survivors. Curr Oncol. 2017;24(6):494. doi:10.3747/co.24.3335
   PubMed Web of Science ®Google Scholar
• AbusiefME, MissmerSA, GinsburgES, WeeksJC, PartridgeAH. The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer. Cancer. 2010;116(4):791–798. doi:10.1002/cncr.2483520052714
   PubMed Web of Science ®Google Scholar
• TolaneySM, BarryWT, DangCT, et al. Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer. N Engl J Med. 2015;372(2):134–141. doi:10.1056/NEJMoa140628125564897
   PubMed Web of Science ®Google Scholar
• RuddyKJ, GuoH, BarryW, et al. Chemotherapy-related amenorrhea after adjuvant paclitaxel–trastuzumab (APT trial). Breast Cancer Res Treat. 2015;151(3):589–596. doi:10.1007/s10549-015-3426-z25981899
   PubMed Web of Science ®Google Scholar
• GianniL, PienkowskiT, ImY-H, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, Phase 2 randomised trial. Lancet Oncol. 2016;17(6):791–800. doi:10.1016/S1470-2045(16)00163-727179402
   PubMed Web of Science ®Google Scholar
• PiccartM, ProcterM, FumagalliD, et al. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years’ Follow-Up. J Clin Oncol. 2021:JCO.20.01204. doi:10.1200/JCO.20.01204
   Web of Science ®Google Scholar
• DeeksED. Neratinib: first Global Approval. Drugs. 2017;77(15):1695–1704. doi:10.1007/s40265-017-0811-428884417
   PubMed Web of Science ®Google Scholar
• MartinM, HolmesFA, EjlertsenB, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(12):1688–1700. doi:10.1016/S1470-2045(17)30717-929146401
   PubMed Web of Science ®Google Scholar
• MolinelliC, ParisiF, RazetiMG, et al. Trastuzumab emtansine (T-DM1) as adjuvant treatment of HER2-positive early breast cancer: safety and efficacy. Expert Rev Anticancer Ther. 2020:1–10. doi:10.1080/14737140.2021.1857243
   Web of Science ®Google Scholar
• von MinckwitzG, HuangC-S, ManoMS, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 2019;380(7):617–628. doi:10.1056/NEJMoa181401730516102
   PubMed Web of Science ®Google Scholar
• RuddyKJ, TrippaL, HuJ, et al. Abstract P2-13-02: chemotherapy-related amenorrhea (CRA) after adjuvant trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT trial). In: poster Session Abstracts. Am Assoc Cancer Rese. 2020:P2-13-02-P2-13-02. doi:10.1158/1538-7445.SABCS19-P2-13-02
   Google Scholar
• JohnstonSRD, HarbeckN, HeggR, et al. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE). J Clin Oncol. 2020;38(34):3987–3998. doi:10.1200/JCO.20.0251432954927
   PubMed Web of Science ®Google Scholar
• MayerEL, DueckAC, MartinM, et al. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2021;22(2):212–222. doi:10.1016/S1470-2045(20)30642-233460574
   PubMed Web of Science ®Google Scholar
• PoggioF, BruzzoneM, CeppiM, et al. Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis. ESMO Open. 2018;3(4):e000361. doi:10.1136/esmoopen-2018-00036129942664
   PubMed Web of Science ®Google Scholar
• WinshipAL, GriffithsM, Lliberos RequesensC, SarmaU, PhillipsK-A, HuttKJ. The PARP inhibitor, olaparib, depletes the ovarian reserve in mice: implications for fertility preservation. Hum Reprod. 2020;35(8):1864–1874. doi:10.1093/humrep/deaa12832604417
   PubMed Web of Science ®Google Scholar
• LambertiniM, PreusserM, ZielinskiCC. New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: introducing an “ESMO Open – cancer Horizons” Series. ESMO Open. 2019;4:e000501. doi:10.1136/esmoopen-2019-00050131275617
   PubMed Web of Science ®Google Scholar
• RobertC. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020;11(1):3801. doi:10.1038/s41467-020-17670-y32732879
   PubMed Web of Science ®Google Scholar
• DumaN, LambertiniM. It is time to talk about fertility and immunotherapy. The Oncologist. 2020;25(4):277–278. doi:10.1634/theoncologist.2019-083732091651
   PubMed Web of Science ®Google Scholar
• PostowMA, SidlowR, HellmannMD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–168. doi:10.1056/NEJMra170348129320654
   PubMed Web of Science ®Google Scholar
• ThompsonJA. New NCCN Guidelines: recognition and Management of Immunotherapy-Related Toxicity. J Natl Compr Canc Netw. 2018;16(5S):594–596. doi:10.6004/jnccn.2018.004729784734
   PubMed Web of Science ®Google Scholar
• BernhardJ, ZahriehD, Castiglione-GertschM, et al. Adjuvant Chemotherapy Followed By Goserelin Compared With Either Modality Alone: the Impact on Amenorrhea, Hot Flashes, and Quality of Life in Premenopausal Patients—The International Breast Cancer Study Group Trial VIII. J Clin Oncol. 2007;25(3):263–270. doi:10.1200/JCO.2005.04.539317159194
   PubMed Web of Science ®Google Scholar
• SinhaN, LetourneauJM, WaldK, et al. Antral follicle count recovery in women with menses after treatment with and without gonadotropin-releasing hormone agonist use during chemotherapy for breast cancer. J Assist Reprod Genet. 2018;35(10):1861–1868. doi:10.1007/s10815-018-1203-830066303
   PubMed Web of Science ®Google Scholar
• LambertiniM, BoniL, MichelottiA, et al. Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: a randomized clinical trial. JAMA. 2015;314(24):2632. doi:10.1001/jama.2015.1729126720025
   PubMed Web of Science ®Google Scholar
• LeonardRCF, AdamsonDJA, BertelliG, et al. GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial. Ann Oncol. 2017;28(8):1811–1816. doi:10.1093/annonc/mdx18428472240
   PubMed Web of Science ®Google Scholar
• MooreHCF, UngerJM, PhillipsK-A, et al. Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230. JNCI J Natl Cancer Inst. 2019;111(2):210–213. doi:10.1093/jnci/djy18530371800
   PubMed Web of Science ®Google Scholar
• LambertiniM, CeppiM, PoggioF, et al. Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. Ann Oncol. 2015;26(12):2408–2419. doi:10.1093/annonc/mdv37426347105
   PubMed Web of Science ®Google Scholar
• RugoHS, RosenMP. Reducing the long-term effects of chemotherapy in young women with early-stage breast cancer. JAMA. 2011;306(3). doi:10.1001/jama.2011.1019
   Web of Science ®Google Scholar
• ZhangY, JiY, LiJ, et al. Sequential versus simultaneous use of chemotherapy and gonadotropin-releasing hormone agonist (GnRHa) among estrogen receptor (ER)-positive premenopausal breast cancer patients: effects on ovarian function, disease-free survival, and overall survival. Breast Cancer Res Treat. 2018;168(3):679–686. doi:10.1007/s10549-018-4660-y29332135
   PubMed Web of Science ®Google Scholar
• ReganMM, WalleyBA, FrancisPA, et al. Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT. Ann Oncol. 2017;28(9):2225–2232. doi:10.1093/annonc/mdx28528911092
   PubMed Web of Science ®Google Scholar
• Dolmans-M-M, TaylorHS, Rodriguez-WallbergKA, et al. Utility of gonadotropin-releasing hormone agonists for fertility preservation in women receiving chemotherapy: pros and cons. Fertil Steril. 2020;114(4):725–738. doi:10.1016/j.fertnstert.2020.08.01133040981
   PubMed Web of Science ®Google Scholar
• AndersonRA, ClatotF, DemeestereI, et al. Cancer survivorship: reproductive health outcomes should be included in standard toxicity assessments. Eur J Cancer. 2021;144:310–316. doi:10.1016/j.ejca.2020.11.03233385947
   PubMed Web of Science ®Google Scholar